SCHEMBL194096

SCHEMBL194096

Clc1cc(Cl)c(Cl)nn1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29549708 1.00
SCHEMBL31425702 0.71
SCHEMBL2646498 0.71
SCHEMBL31465413 0.71
SCHEMBL10321593 0.71
SCHEMBL23932248 0.71
SCHEMBL14074055 0.71
SCHEMBL2936869 0.71
SCHEMBL11255439 0.71
SCHEMBL30930706 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 663 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118005615-A Pyridazine compound and preparation method, pharmaceutical composition and application thereof 中国药科大学 2024-05-10 CN claimed
CN-113698355-B Synthesis method of 4, 5-dihydroxypyridazine 郑州华赞医药科技有限公司 2023-05-26 CN claimed
CN-113698355-A Synthesis method of 4, 5-dihydroxypyridazine 郑州华赞医药科技有限公司 2021-11-26 CN claimed
US-12637468-B2 Substituted [1,2,4]triazolo[4,3-b]pyridazines as GABAA receptor modulators Shanghai Simr Biotechnology Co., Ltd. (CN) 2026-05-26 US disclosed
WO-2026090330-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2026-04-30 WO disclosed
WO-2026090411-A1 BRM AND BRG1 TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE PRELUDE THERAPEUTICS INCORPORATED (US) 2026-04-30 WO disclosed
EP-4727944-A1 [1,2,4]-TRIAZOLO[4,3-B]PYRIDAZINE DERIVATIVES USEFUL AS A MEDICAMENT Perha Pharmaceuticals (FR) 2026-04-22 EP disclosed
EP-4129986-B1 SUBSTITUTED PYRIDAZINE COMPOUND TENVIE THERAPEUTICS INC (US) 2026-03-11 EP disclosed
US-12569485-B2 SMARCA inhibitors and uses thereof KYMERA THERAPEUTICS, INC. (US) 2026-03-10 US disclosed
US-20260055065-A1 PYRIDAZINONE COMPOUNDS WHICH MODULATE MUTANT PROTEINS FOR TREATING RESPIRATORY DISEASES HOSPITAL FOR SICK CHILDREN (CA) 2026-02-26 US disclosed
EP-4692090-A1 TRICYCLIC COMPOUND AS ATR KINASE INHIBITOR Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (CN) 2026-02-11 EP disclosed
US-6391883-B1 INSECTICIDES SYNGENTA LIMITED (GB) 2002-05-21 US disclosed
EP-1195378-A1 Pyridotriazines and pyridopyridazines WARNER-LAMBERT COMPANY (US) 2002-04-10 EP disclosed
US-6207676-B1 Bicyclic amines ZENECA LIMITED (GB) 2001-03-27 US disclosed
EP-0828739-A1 BICYCLIC AMINES AS INSECTICIDES ZENECA LIMITED (GB) 1998-03-18 EP disclosed
WO-1996037494-A1 BICYCLIC AMINES AS INSECTICIDES ZENECA LIMITED (GB) 1996-11-28 WO disclosed
EP-0372305-B1 PIPERAZINYLALKYL-3(2H)-PYRIDAZINONES, METHOD FOR THEIR PREPARATION AND THEIR USE AS ANTIHYPERTENSIVE AGENTS Hafslund Nycomed Pharma Aktiengesellschaft (AT) 1993-08-04 EP disclosed
US-5034391-A Piperazinylalkyl-3(2H)-pyridazinones and the use thereof as agents lowering blood pressure CL PHARMA AKTIENGESELLSCHAFT (AT) 1991-07-23 US disclosed
EP-0372305-A1 Piperazinylalkyl-3(2H)-pyridazinones, method for their preparation and their use as antihypertensive agents Hafslund Nycomed Pharma Aktiengesellschaft (AT) 1990-06-13 EP disclosed
US-3978057-A HYPOTENSIVE AGENTS SANDOZ, INC. (US) 1976-08-31 US disclosed